Kura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk

Dow Jones

Nov 21, 2024

0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. (ben.glickman@wsj.com; @benglickman)

(END) Dow Jones Newswires

November 21, 2024 09:16 ET (14:16 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2485771494"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485771494\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485771494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485771494","market":"us","top_or_hot":-1,"title":"Kura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. (ben.glickman@wsj.com; @benglickman) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2024 09:16 ET (14:16 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-21 22:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. (ben.glickman@wsj.com; @benglickman) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2024 09:16 ET (14:16 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485771494","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485771494","pubTimestamp":1732198560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","KURA":"Kura Oncology, Inc","BK4139":"生物科技","ISBC":"投资者银行","BK4211":"区域性银行"},"translate_title":"Kura Oncology的商业化交易并不是投资者想要的——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURA":1,"ISBC":1},"content_text":"0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. (ben.glickman@wsj.com; @benglickman) \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2024 09:16 ET (14:16 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}